Literature DB >> 2699195

Depression, antidepressants, and body weight change.

M H Fernstrom1.   

Abstract

The excessive weight gain observed during treatment of depression with antidepressant medications is caused in part, at least in some persons, by reductions in resting metabolic rate. Such problematic weight gain appears unrelated to clinical recovery, weight change during the depressive episode, prior weight, or other related factors. Preliminary results suggest that increased energy efficiency (of about 16-24%) during treatment with tricyclic antidepressants could promote weight gain even in the absence of a change in caloric intake. This is not a property of all antidepressants, as demonstrated by the increase in metabolic rate and associated weight loss observed during treatment with the monocyclic antidepressant compound fluvoxamine. Should these serotonergic compounds continue to be effective antidepressants, they may be better accepted by patients, and their use help avoid medication noncompliance. In considering energy balance and weight change, our focus has been drawn to altered metabolic rate. Continuing studies do not suggest an effect of antidepressants on appetite, particularly the presence of "carbohydrate craving," either during treatment or during a depressive episode. Certainly, a notable preference for highly palatable foods (rich in fats and carbohydrates) occurs during the depressive episode, but not during treatment. These foods cannot be labeled carbohydrates.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2699195     DOI: 10.1111/j.1749-6632.1989.tb53229.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  10 in total

1.  Ingestion and emotional health.

Authors:  N K Dess
Journal:  Hum Nat       Date:  1991-09

Review 2.  Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.

Authors:  H Pijl; A E Meinders
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

3.  Depression and glycemic intake in the homebound elderly.

Authors:  D Mkaya Mwamburi; Elizabeth Liebson; Marshal Folstein; Kathleen Bungay; Katherine L Tucker; Wei Qiao Qiu
Journal:  J Affect Disord       Date:  2011-03-11       Impact factor: 4.839

4.  Attenuation of antipredator defensive behavior in rats following chronic treatment with imipramine.

Authors:  R J Blanchard; J K Shepherd; R J Rodgers; L Magee; D C Blanchard
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Serotonin transporter gene promoter polymorphism is associated with body mass index and obesity in non-elderly stroke patients.

Authors:  M Y Lan; Y Y Chang; W H Chen; Y F Kao; H S Lin; J S Liu
Journal:  J Endocrinol Invest       Date:  2009-02       Impact factor: 4.256

6.  Dietary glycaemic load and odds of depression in a group of institutionalized elderly people without antidepressant treatment.

Authors:  A Aparicio; F Robles; A M López-Sobaler; R M Ortega
Journal:  Eur J Nutr       Date:  2012-07-12       Impact factor: 5.614

Review 7.  Tolerability and safety of fluvoxamine and other antidepressants.

Authors:  H G M Westenberg; C Sandner
Journal:  Int J Clin Pract       Date:  2006-04       Impact factor: 2.503

8.  Caffeine protects against stress-induced murine depression through activation of PPARγC1α-mediated restoration of the kynurenine pathway in the skeletal muscle.

Authors:  Chongye Fang; Shuhei Hayashi; Xiaocui Du; Xianbin Cai; Bin Deng; Hongmei Zheng; Satoshi Ishido; Hiroko Tsutsui; Jun Sheng
Journal:  Sci Rep       Date:  2021-03-31       Impact factor: 4.379

9.  Association of adenovirus 36 infection with obesity and metabolic markers in humans: a meta-analysis of observational studies.

Authors:  Tomohide Yamada; Kazuo Hara; Takashi Kadowaki
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

10.  The depressive-like behaviors of chronic unpredictable mild stress-treated mice, ameliorated by Tibetan medicine Zuotai: involvement in the hypothalamic-pituitary-adrenal (HPA) axis pathway.

Authors:  Jing Zhao; Cuiying Niu; Jianv Wang; Hongxia Yang; Yuzhi Du; Lixin Wei; Cen Li
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-03       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.